The clinical course of breast cancer varies from one patient to another. Currently, the choice of therapy relies on clinical parameters and histological and molecular tumor features. Alas, these markers are informative in only a subset of patients. Therefore, additional predictors of disease outcome would be valuable for treatment stratification. Extensive studies showed that the degree of variation of the nuclear DNA content, i.e., aneuploidy, determines prognosis. Our aim was to further elucidate the molecular basis of aneuploidy. We analyzed five diploid and six aneuploid tumors with more than 20 years of follow-up. By performing FISH with a multiplexed panel of 10 probes to enumerate copy numbers in individual cells, and by sequencing 563 cancer-related genes, we analyzed how aneuploidy is linked to intratumor heterogeneity. In our cohort, none of the patients with diploid tumors died of breast cancer during follow-up in contrast to four of six patients with aneuploid tumors (mean survival 86.4 months). The FISH analysis showed markedly increased genomic instability and intratumor heterogeneity in aneuploid tumors. MYC gain was observed in only 20% of the diploid cancers, while all aneuploid cases showed a gain. The mutation burden was similar in diploid and aneuploid tumors, however, TP53 mutations were not observed in diploid tumors, but in all aneuploid tumors in our collective.
of patients to systemic therapy are more variable in breast cancer than in many other types of cancer. 3 However, even at an early stage, tumor-intrinsic genetic alterations affect tumor growth, progression and metastatic potential and therefore limit the value of commonly used prognostic markers. In many cases, the current standard of care does not correctly assess a patient's prognosis. 4 To improve prognostication, gene expression profiling has been added into clinical management. A commonly used test is OncotypeDX (Genomic Health), which is included in the current ASCO breast cancer guidelines. 5, 6 OncotypeDX is applied to stratify early stage breast cancer and measures the expression of 21 genes resulting in a score, which can predict the risk of disease recurrence as well as the potential benefit from chemotherapy. 7 Additional gene expression tests such as MammaPrint, Prosigna, or EndoPredict are currently under evaluation in prospective clinical trials. 6, 8, 9 In addition to specific gene expression profiles, extensive studies measuring nuclear DNA content showed that the degree of aneuploidy determines disease outcome. [10] [11] [12] [13] In general, patients with genomically stable tumors have a significantly better prognosis compared to patients whose tumors are aneuploid. We have previously determined a gene expression signature of chromosomal instability, which recapitulated the expression signatures of both OncotypeDX and Mammaprint. 14 We
showed that general aneuploidy is reflected in these expression profiles and lays the genetic basis for poor prognosis. However, it remains unclear how aneuploidy is reflected by chromosomal gains and losses in individual cells across the tumor population, and to what extent aneuploidy drives intratumor heterogeneity (ITH). It is also unclear whether aneuploidy correlates with the gene mutation frequency.
To address these questions, we used multiplex interphase FISH (miFISH) with a panel of eight genes commonly subject to copy number changes in breast cancer to determine the extent of ITH due to copynumber variation, and applied targeted sequencing of a panel of 563 cancer-associated genes for the analysis of five diploid and six aneuploid breast cancers from individuals with comprehensive clinical annotation, including a 20-year follow-up period.
| M A TE RI A L S A ND M E TH ODS

| Tumor samples
Based on DNA content measurements, we selected diploid and aneuploid samples from a cohort of breast cancer patients with a follow-up of at least 20 years, who were treated in Stockholm, Sweden and enrolled in the Stockholm county epidemiological registry. We chose approximately equal group sizes for the diploid and aneuploid tumors.
No additional selection criteria were applied. Clinical data were collected during treatment and follow-up. Use of samples and data for this study were approved by the local ethics committee.
| Quantitative measurement of the nuclear DNA content
Nuclear DNA content was measured quantitatively after Feulgen staining as described using static image analysis, which converts the computer-aided extinction coefficient of the stained cells into a ploidy degree. 13 Around 100-200 tumor cells and 10-20 lymphocytes (serving as diploid reference cells) were measured per case. The DNA histograms (see Figure 1 and Supporting Information File S1 were then classified according to Auer et al. 10 
| Preparation of sections and cytospins from archived tumor blocks
All experiments were performed on formalin-fixed, paraffin-embedded (FFPE) tumor blocks, from which four sections (thickness: 4 lm, 50 lm, 50 lm, 4 lm) were consecutively prepared. The 4 lm sections were stained with hematoxylin and eosin (H&E) and representative tumor areas were marked on all slides by a pathologist. One 50 lm section was used to prepare cytospins for the miFISH analysis. 15 The other 50 lm section was used for sequencing. The representative areas were macrodissected, deparaffinized in xylene, rehydrated and digested with protease. Tissue disintegration was monitored under microscopic control. Once it was judged to be optimal, the reaction was stopped and the density of the single cell suspension was adjusted to achieve medium dense, monolayered cytospins when loading 80-120 ml of suspension into a Shandon cytospin centrifuge.
| Multiplex interphase fluorescence in situ hybridization (miFISH)
Bacterial artificial chromosome contigs consisting of three to four overlapping clones were assembled targeting the following eight breast cancer associated genes:
CCND1 (11q13.3), CDH1 (16q22.1), HER2 (17q12), TP53 (17p13.1), and ZNF217 (20q31.2). All clones were labeled by nick translation with fluorochromes DY-415-dUTP (ZNF217, MYC), DY-505-dUTP (CDH1, CCND1), DY-547P1-dUTP (TP53, DBC2) and DY-590-dUTP (HER2, COX2). The two centromere probes, CEP4 and CEP10, were labeled with DY-651. All fluorochrome conjugates were purchased from Dyomics (Jena, Germany). The FISH probes were combined into two panels:
ZNF217, HER2, TP53, CDH1, CEP10, and MYC, COX2, DBC2, CCND1, CEP4. The two panels were consecutively hybridized onto the same cytospins, so that all 10 probes could be enumerated in each nucleus.
The miFISH procedure was performed as previously described. 15 Across the 11 samples, 12,000 nuclei were automatically imaged with a fluorescence microscope and a 40x oil immersion objective (BX63, Olympus, Tokyo, Japan) equipped with custom optical filters (Chroma, Bellow Falls, VT, USA) with a motorized stage and custom scanning and analysis software (BioView, Rehovot, Israel). For the consecutive hybridizations, the coverslip was removed and the slides were washed in 2xSSC, stripped in 70%FA/2xSSC at 808C for one minute, dehydrated and air-dried. The slides were then re-hybridized with panel 2 prior to a second scan. Images for subsequent hybridizations were automatically overlaid for the same target nuclei. Nuclei and signal counts for all 10 FISH probes were presented in a custom gallery overview (BioView), which allows for manual correction of the automated counts. Enumeration was performed in a consecutive manner. Nuclei were excluded from analysis if (i) they overlapped with another nucleus, (ii) the nucleus was damaged or incomplete or (iii) at least one probe signal was not clearly visible. For nine cases 400 interphase nuclei were evaluated; for cases A3 and A4 300 nuclei were evaluated due to a lower number of cells available that met the three inclusion/ exclusion criteria.
| Determining clonal signal patterns and instability indices
Excel spreadsheets of signal counts were automatically recorded and exported for subsequent analysis. These spreadsheets contained signal showed also a diploid cell population. However, the diploid cells detected in this case by miFISH showed two copies for every FISH probe and were therefore not included in the miFISH analysis as explained above.
We subsequently applied a program that compares the gene signal counts to the ploidy of each cell, which allowed us to translate the signal count of each probe into either "gained" 
| Phylogenetic tree inference
Tree models of tumor progression were computed using the software 
| Targeted next generation sequencing
For each case, DNA was extracted from a representative area of a 50 mm section using proteinase K digestion as previously described. 17 Targeted next generation sequencing was performed with a capture assay, termed OncoVar, which was designed to sequence coding exons of 563 cancer related genes. 18 The resulting paired-end libraries were sequenced on Illumina NextSeq 500 sequencers (Illumina, San Diego, CA, USA).
| Sequencing data processing and analysis
Our data processing and variant calling procedure mainly followed the Best Practices workflow recommended by the Broad Institute. Briefly, the raw sequencing reads were mapped to human genome build 19 by
Burrows-Wheeler Aligner 19 followed by local realignment using the GATK suite from the Broad Institute and duplicated reads were marked by Picard tools. The UnifiedGenotyper from the Broad Institute was used to call variants. 20 Multiple annotation databases, including dbNSFP, 21 dbSNP 147 (NCBI), 22 ESP6500 (NHLBI Exome Sequencing Project), and the COSMIC database 23 were used to annotate and predict the effects of variants.
The following filtering criteria were used to drop a fraction of the variant calls: 1) did not pass variant caller filters; 2) fraction of alternative reads <5 5%; 3) reference read depth <5 5 and alternative read depth <5 3; 4) QUAL <30; 5) MAPQ score < 55; 6) low impact according to dbNSFP. The fifth criterion was relaxed for two PIK3CA
variants with >200 occurrences in COSMIC. They have MAPQ 5 48.1 and 54.1, respectively, and were visually validated by several people independently. 24 Then, we did two types of allele frequency filtering. 
| Statistics
Two-tailed t-tests were used to calculate p-values for comparisons between diploid and aneuploid tumors.
| RE S U L TS
The degree of aneuploidy, defined as deviations from a diploid genome and determined by quantitative measurements of the nuclear DNA content, profoundly influences disease outcome of patients with breast cancer. 10 Here, we aimed to (i) understand patterns of aneuploidy by copy number analysis of multiple gene loci in single cells, to (ii) quantify the extent of ITH, and to (iii) identify gene mutation spectra associated with aneuploidy and poor survival.
| Clinical data
The clinical data, including age at diagnosis, clinical tumor stage and tumor size, estrogen receptor (ER) and progesterone receptor (PR) receptor status, the occurrence of local relapse and distant metastases during follow-up, and survival, together with the results of the miFISH and sequence analyses are summarized in Table 1 . 
COX2,DBC2,
TP53, HER2
Yes EPH86 (S172_173dup), BC, breast cancer; CCVD, chronic cardiovascular disease; ER, estrogen receptor; PR, progesterone receptor. The age reflects the age at diagnosis. All local relapses and distant metastases during follow-up were documented. Instability index is calculated as number of signal patterns 3 100 / number of cells analyzed.
Major signal patterns: Copy numbers higher than the ploidy (first number) are bolded (gains), copy numbers lower than the ploidy are in light gray (losses). Patterns in parenthesis are diploid clones observed in a subpopulation in an aneuploid lesion and are therefore not included in the average percentage of the major signal pattern clone for the aneuploid lesions. Percentages for the diploid and aneuploid signal pattern clones in cases A1 and A3 are calculated separately within the diploid and the aneuploid cell populations of these cases. In this study, we targeted eight breast cancer relevant genes:
| Quantification of DNA ploidy
(16q), TP53 (17p), HER2 (17q), and ZNF217 (20q). These genes were selected because they map to chromosome arms frequently subject to copy number alterations in breast cancer, as previously determined by comparative genomic hybridization. 30, 31 Probes that target the centro- Case D1 revealed a pattern consistent with the formation of an isochromosome 8q in 67% of cells, an isochromosome also previously reported in the literature, 32 accompanied by losses of CDH1 and TP53.
Case D2 showed an isochromosome 17q and a gain of CCND1 as the major clone pattern in 67% of cells (an isochromosome 17q was also present in case D4 as the sole event in 86% of cells). In case D3, the Average no. of changes/lesion 2. 
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The genes that were most frequently subject to copy number gains were MYC and COX2 (1/5 and 1/5 diploid cases, and 6/6 and 5/6
aneuploid cases, respectively), while TP53 and CDH1 were most commonly lost (4/5 and 3/5 in diploid cases, and 6/6 and 5/6 in aneuploid cases, respectively) (see Table 2 ). Of note, TP53 was lost in almost all samples with the exception of one diploid case (D5) which was characterized by a very clonal loss of CDH1. The difference in frequencies of MYC copy number gains between diploid and aneuploid tumors was statistically significant (P 5 .01).
We display the trajectory of tumor evolution graphically in Figure   2 . We show examples in which the tumor evolution in a diploid tumor follows a rather simple path (case D4), or paths that display a greatly 
| Landscape of gene mutations
To assess the protein-altering mutations, in the tumor samples we used targeted sequence analysis of 563 cancer-related genes (see Materials and Methods
18
). Table 1 In summary, we quantitatively measured the nuclear DNA content of 11 breast cancer samples from patients with good or poor prognosis.
The genetic consequences of crude DNA ploidy levels in the tumor population were determined by miFISH and revealed both a higher 
| Differences between diploid and aneuploid tumors
We assessed the following clinical and genetic parameters in diploid versus aneuploid tumors: patient age at diagnosis, tumor size, hormone receptor status, lymph node positivity, the occurrence of local relapse and distant metastases, overall survival, chromosomal instability index (number of signal patterns x100 divided by the number of cells), presence of major clones (determined by FISH), and mutations in a set of 563 cancer associated genes. 18 The mean age at time of diagnosis of the patients with diploid tumors was 62.8 years versus 52 years for patients with aneuploid tumors. This is consistent with a generally poorer prognosis for younger breast cancer patients. 34 The mean tumor size in patients with diploid tumors was 12. Half of these patients presented with distant metastases (Table 1 ). The correlation of these clinical parameters with overall survival is consistent with the literature. 35 The most pronounced genetic difference between the diploid and aneuploid tumors was the instability index calculated based on differential FISH signal patterns observed per 100 nuclei, which was on average 3.4 times higher in aneuploid tumors. Heterogeneity is also reflected by the percentage of cells with identical signal count patterns in the tumor cell population (i.e., clones). Comparing the size of the major signal pattern clones, the degree of ITH was 6.3 times higher in the aneuploid tumors. This could be interpreted such that the degree of "genomic nimbleness" greatly facilitates the propensity to acquire a tumor genotype conducive for rapid proliferation, for the development of metastatic disease, and for the development of treatment resistance. This is consistent with the results from one of our previous studies in which we measured overall genomic instability and ITH in matched DCIS and IDC samples. 15 In that study, we observed increased ITH often already in the DCIS lesion. We also detected copy number increase of MYC as a major determinant of progression from DCIS to IDC. In the present study, we observed MYC copy number gains in all aneuploid tumors, yet in only 1/5 diploid tumors.
The difference in the degree of chromosomal instability and ITH in the tumors analyzed here can be readily appreciated from Figure 1A -C, showed only losses of CDH1, while minor clones in 2% of the populations had either an additional loss of TP53 or a gain of MYC. Such a pattern would in principle be beneficial for the growth of breast cancer, however, these clones were either not fitter in the cancer cell population or, did not have the time yet to outcompete the dominant clone.
The pattern in D4, on the other hand, suggests that an isochromosome 17q is more advantageous in the population (86%) when compared to just a loss of TP53 (3%). Surprisingly, we observed a signal pattern in four cases indicative of a loss of the entire chromosome 17 (D3, A1, A3, and A4). This leads to the interpretation that the loss of TP53 might be more relevant than the gain of HER2, or could be a reflection of the OLTMANN ET AL.
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fact that the loss of a chromosome (i.e., a numerical aberration) is easier to achieve than the creation of an isochromosome (which requires structural changes).
In terms of the overall mutation frequency per case, the differences were less pronounced compared to chromosomal copy number changes. In fact, aneuploid tumors had on average 3.3 mutations, while diploid tumors showed 2.8 mutations per case. One striking distinction, however, is that all aneuploid tumors carried inactivating (frameshift or premature stop codon) mutations of TP53 (see Additional File 3), which
were not observed in diploid tumors. In addition to mutations, all aneuploid tumors showed losses of this tumor suppressor, indicating that the development of crude aneuploidy apparently requires the loss of function of TP53 (Table 1 ).
In summary, increased intratumor heterogeneity measured by 
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